Simcerely Yours: Simcere Buys Majority Stake In Fellow Chinese Pharma Boda
This article was originally published in PharmAsia News
Executive Summary
Continuing its acquisition strategy, Simcere Pharmaceutical Group, one of China's largest branded generics manufacturers, bought a 51 percent stake in Boda Pharmaceutical in a deal valued at $14.8 million (RMB 111 million), Simcere announced Sept. 28
You may also be interested in...
Chinese Simcere Reports Fourth Quarter Sales Growth; Preparing For Health Care Reforms
SHANGHAI - China-based Simcere Pharmaceutical Group reported a spike in the sales of its two main products, anti-cancer drug Endu and injectable edaravone Bicun in its fourth quarter 2007 financial results.
Chinese Simcere Reports Fourth Quarter Sales Growth; Preparing For Health Care Reforms
SHANGHAI - China-based Simcere Pharmaceutical Group reported a spike in the sales of its two main products, anti-cancer drug Endu and injectable edaravone Bicun in its fourth quarter 2007 financial results.